---
title: Symbiotec Pharmalab Listing: Shares had a flat listing on NSE (₹988) and at a 0.99% (₹978.20) discount on BSE
url: https://dhan.co/blog/ipo/symbiotec-pharmalab-shares-listing/
page_type: blog_post
last_updated: 2026-09-01
---

# Symbiotec Pharmalab Listing: Shares had a flat listing on NSE (₹988) and at a 0.99% (₹978.20) discount on BSE

Symbiotec Pharmalab Limited had a flat listing despite having a grey market premium (GMP) of approximately ₹185 the day before listing, indicating an estimated listing price of ₹1173.

### Key takeaways:

- Symbiotec Pharmalab had a flat debut at ₹988 on the NSE and at a 0.99% discount at ₹978.20 on the BSE.
- The public issue of ₹1,757.00 crore was oversubscribed by a whopping 75.08 times, with overwhelming demand from institutional buyers.
- Strong institutional confidence was evident as the Qualified Institutional Buyers (QIBs) quota was subscribed 181.20 times.
- The Symbiotec Pharmalab IPO subscription window started on August 24, 2026 and ended on August 27, 2026.
- The company has a strong global presence, with its corticosteroid and steroidal-hormone APIs being exported globally.

Symbiotec Pharmalab Limited, a leading manufacturer of active pharmaceutical ingredients (APIs), today debuted on the Indian capital markets. The company went public by listing its equity shares on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The initial public offering (IPO) of ₹1,757.00 crore included a fresh issue of ₹150 crore and an offer for sale (OFS) of 1.63 crore shares worth ₹1,607 crore by existing shareholders.

[Symbiotec Pharmalab Limited shares](https://dhan.co/stocks/symbiotec-pharmalab-ltd-share-price/) had a flat listing debut on NSE at ₹988 and at a discount of 0.99% on the BSE at 978.20, against the upper price band of ₹988 per share. Let’s explore Symbiotec Pharmalab's listing performance and IPO journey in detail.

## Symbiotec Pharmalab listing performance

Symbiotec Pharmalab's shares were officially listed on the Indian stock exchanges on September 1, 2026. The shares are listed at ₹988 on the NSE, delivering no premium/discount, while on the BSE, they are listed at ₹978.20, at a 0.99% discount to the issue price of ₹988.

The IPO's massive demand was driven by its extensive global market presence, complex API manufacturing capabilities, and high-margin, export-oriented business model.

## About Symbiotec Pharmalab

Symbiotec Pharmalab was incorporated in 2002 and is a research-oriented pharmaceutical company specialising in the development and manufacturing of Active Pharmaceutical Ingredients (APIs). The company has a diversified portfolio of over 60 APIs and has established a strong niche in the business of corticosteroid and steroidal-hormone APIs.

It is well established in the domestic and international markets and a large share of its revenues is generated from exports. Symbiotec has dedicated production, fermentation and injectable facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and a fermentation capacity of 300 kilolitres.

The company has its own product line and also offers contract development and manufacturing (CDMO) services to pharmaceutical and nutraceutical customers around the world, holding several international regulatory certifications.

The company has shown consistent financial growth in the last few years. Symbiotec Pharmalab's total income increased from ₹755.98 crore in FY25 to ₹872.26 crore in FY26. Additionally, its profit after tax (PAT) also increased from ₹96.79 crore in FY25 to ₹109.90 crore in FY26.

## Symbiotec Pharmalab IPO journey

The [Symbiotec Pharmalab IPO](https://dhan.co/ipo/symbiotec-pharmalab-ipo/) subscription window opened on August 24, 2026 and remained open till August 27, 2026. The company offered shares at a price band of ₹938 to ₹988 per equity share with a minimum retail lot size of 15 shares.

The IPO was a book-built issue of ₹1,757 crore, including an offer for sale (OFS) of ₹1,607 crore by the existing promoters and shareholders and a small fresh issue of ₹150 crore. The IPO achieved a total subscription of 75.08 times. The retail segment oversubscribed its quota by 13.69 times, and the Non-Institutional Investors (NII) category was oversubscribed by 77.56 times.

The QIBs were quite aggressive in bidding for the issue and subscribed to their quota by an impressive 181.20 times, reflecting the strong institutional conviction in the company's fundamentals. This IPO employees segment was subscribed 16.32 times.

## Wrap up

The listing of Symbiotec Pharmalab on Indian exchanges highlights the rising investor interest in specialised healthcare and API manufacturing companies in India. The flat market debut of Symbiotec Pharmalab shares reflects the broader negative sentiment in the market.

It still remains an appealing investment opportunity for long-term investors, driven by its extensive export business, diversified steroid-hormone product portfolio, and strong institutional support.

As the company moves forward as a publicly listed company, its ability to navigate global pharmaceutical regulations, scale its high-margin APIs, and expand its global footprint will be key to future growth.
